INDIA-EU FTA unlocks access to $572.3 billion EU pharmaceuticals & medical devices market

Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents

Care ADHD opens its first Global Capability Centre in India

UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country

Shilpa Medicare receives initial authorization for Rotigotine transdermal patch from Europe

This is the first approval of a prescription transdermal dosage Form in the European markets from this facility

Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI

This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States

Solara’s Mangalore facility clears FDA inspection with VAI status

DMMA warns regulatory burden threatening Gujarat’s pharma MSMEs

The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.

Shilpa Medicare receives initial authorization for Rivaroxaban Orodispersible films from EMA

President Murmu graces diamond jubilee celebrations of All India Institute of Speech and Hearing, Mysuru

Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru

This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms

Shilpa Medicare Unit VI facility at Dabaspet receives GMP certification from SFDA

This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product